I saw the ceres nano is being employed for Lyme testing, which is very cool. I saw, too, the normal WB is also being used.
Since the usual caveats (antigenic variance, etc.) may apply here, I was wondering if there is anything being done to reduce problems associated with testing being pigeon-holed to a strain or two. Any Borrelia testing on a genus level? Or testing for as many species and strains as possible that we have knowledge of? For instance, testing to ensure no b miyamotoi or afzelii or garinii or any other very different species of Borrelia whose symptoms mimic ME/CFS and conventional Lyme - but are not picked up by US Lyme metrics - are culprits in a portion of our community?
I know Mark Davis is working on some Lyme stuff, but that effort is restricted to the San Fran area - which means strain(s) will likely be indiginous, and potentially different than, say, Connecticut or Kansas.
Sooooo, how does one discount Borrelia, if only one or two Borrelia, out of 36 Species and 300 strains already known to be on the table, are being tested for?
btw, similar strain issues also beset Bartonella testing, a disease that also is fond of chronicity.
I do realize there are costs here, and the testing already proposed is extra-ordinarily comprehensive and ambitious. It's just that, how can we rule in or out any pathogen if we are not adaquetly sweeping the field for it? I am hopeful that this team which is doing so much already, is trying to resolve this dilemma.